HCA Healthcare, Inc. $HCA Stake Reduced by Patten & Patten Inc. TN

Key Points

• Patten & Patten Inc. TN reduced its stake in HCA Healthcare by 4.7% in the second quarter, holding 13,540 shares valued at approximately $5.19 million.
• HCA Healthcare's stock was recently rated with a consensus price target of $431.07, with most analysts giving it a "Moderate Buy" rating.
• The company announced a quarterly dividend of $0.72, representing a yield of 0.7%, with a payout ratio of 12.11%.

Patten & Patten Inc. TN cut its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 4.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,540 shares of the company's stock after selling 669 shares during the quarter. Patten & Patten Inc. TN's holdings in HCA Healthcare were worth $5,187,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of HCA. Nuveen LLC purchased a new position in HCA Healthcare in the 1st quarter worth about $569,217,000. Pacer Advisors Inc. increased its stake in HCA Healthcare by 6,237.9% in the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company's stock worth $466,815,000 after purchasing an additional 1,329,618 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company's stock worth $829,104,000 after purchasing an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company's stock worth $615,583,000 after purchasing an additional 587,036 shares in the last quarter. Finally, Abdiel Capital Advisors LP purchased a new position in HCA Healthcare during the 1st quarter valued at about $164,835,000. Hedge funds and other institutional investors own 62.73% of the company's stock.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lifted their target price on HCA Healthcare from $360.00 to $370.00 and gave the company a "neutral" rating in a research note on Monday, August 4th. Wells Fargo & Company lifted their target price on HCA Healthcare from $375.00 to $412.00 and gave the company an "equal weight" rating in a research note on Tuesday, October 7th. Bank of America lifted their target price on HCA Healthcare from $375.00 to $410.00 and gave the company a "neutral" rating in a research note on Wednesday, September 10th. Royal Bank Of Canada lowered their price target on HCA Healthcare from $404.00 to $401.00 and set an "outperform" rating for the company in a research note on Monday, July 28th. Finally, Truist Financial set a $460.00 price target on HCA Healthcare in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, HCA Healthcare currently has an average rating of "Moderate Buy" and a consensus price target of $431.07.

HCA Healthcare Stock Performance

HCA opened at $420.38 on Thursday. The business has a 50 day moving average price of $408.25 and a 200 day moving average price of $377.15. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $439.01. The firm has a market cap of $98.37 billion, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 1.32 and a beta of 1.40.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping the consensus estimate of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The firm had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same period in the previous year, the company earned $5.50 EPS. The company's revenue for the quarter was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date was Tuesday, September 16th. HCA Healthcare's payout ratio is 12.11%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.